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The aim of the present study was to evaluate the relationship between GHRH-induced GH secretion in obese premenopausal
women and cardiovascular risk markers or insulin resistance. Premenopausal obese women, aged 35–52 years, were studied. GH
secretion, IGF-I, serum cardiovascular risk markers, insulin, leptin, mid-waist and hip circumference, total body fat, and truncal
fat were measured. Subjects were classified as meeting the criteria for GH deficiency (GHD) when peak GH after stimulation with
GHRH was ≤3 μg/L. Mean total and LDL cholesterol, fasting insulin, and HOMA-IR were all higher, in subjects who would have
been classified as GH-deficient compared with GH-suﬃcient. Peak GH secretion after stimulation was inversely associated with
fasting insulin (R = −0.650, P = .012), HOMA-IR (R = −0.846, P = .001), total cholesterol (R = −0.532, P = .034), and LDL
cholesterol (R = −0.692, P = .006) and positively associated with HDL cholesterol (R = 0.561, P = .037). These data strongly
suggest a role for insulin resistance in the decreased GH secretion of obesity and that the blunted GH secretion of central obesity
could be the pituitary expression of the metabolic syndrome.
1. Introduction
Several classic studies have shown that GH deficiency (GHD)
in adults is associated with abnormalities in body com-
position, metabolic derangements, and suboptimal phys-
ical performances; these impairments improve with GH
replacement therapy [1–3]. Hypopituitarism is associated
with increased cardiovascular mortality, women are dispro-
portionally aﬀected, and GH deficiency has been considered
a contributory factor [4–6]. The increased mortality is
reflected in elevated cardiovascular risk markers [7–9] and
GH replacement results in improvement in these markers
[10–14].
In obesity there is a markedly decreased GH secretion.
For both children and adults, the greater the body mass index
(BMI), the lower the GH response to provocative stimuli
[15, 16], including the response to GH-Releasing Hormone
(GHRH) [17, 18]. The altered somatotroph function of
obesity is not permanent; it can be reversed by a return to
normal weight [19] or by short-term calorie restriction [20].
The most striking example of reversibility appeared when
obese subjects were treated with GHRH plus GH-Releasing
Peptide-6 (GHRP-6) both at saturating doses, which resulted
in a massive GH response for obese subjects [21]. This
relative GH deficiency may contribute to develop or maintain
the obese state [22] and GH treatment has been employed
in obesity [23–26]. A recent meta-analysis of recombinant
human GH as therapy for obesity in adults suggests that
GH therapy leads to a decrease in visceral adiposity and
increase in lean body mass as well as beneficial changes in
lipid profile in obese adults, without inducing weight loss
[25].
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However, little is known about whether the association
between decreased GH secretion and increased cardiovas-
cular risk markers observed in patients with GHD and
hypopituitarism occurs in obese patients without organic
hypothalamic or pituitary disease. There are some recent
interesting studies that have evaluated the relationship
between GH secretion, evaluated by GHRH-arginine test-
ing and cardiovascular risk markers or central adiposity
measures. Makimura et al. found that the GH response to
GHRH-arginine testing is reduced in both overweight and
obese men and negatively associated with indices of central
abdominal obesity including waist circumference, trunk fat,
and visceral adipose tissue. They also found that the use
of waist circumference adds predictive information to the
determination of GH response, independent of BMI [27].
Utz et al. found that HDL was lower, high-sensitivity C-
reactive protein (hsCRP) and tumour necrosis factor-α (TNF-
α) receptor I higher, in young overweight or obese women
meeting GHD criteria than in women with GH suﬃciency.
These diﬀerences remained significant after controlling for
age plus BMI, waist circumference, or trunk fat; there
were no diﬀerences in measures of insulin resistance [28].
Carmichael et al. found that peak GH response to GHRH-
arginine, in a population of adults aged 50–90 years, was
significantly related to fasting glucose, insulin, BMI, HDL
cholesterol, triglycerides, trunk fat, and abdominal subregion
fat, with fasting glucose ranking first by multiple regression
analysis [29].
The most clearly altered GH secretion test in obesity
is GHRH-induced GH secretion [18, 21, 30, 31], due
to this markedly decreased GH secretion; it should be
especially attractive to study its relationship with diﬀerent
cardiovascular risk factors in a homogenous population. We
studied women of reproductive age because data in this
group are particularly lacking, and it is very important to
identify risk factors for future cardiovascular disease in this
population. The aim of the present study was to evaluate the
relationship between GHRH-induced GH secretion in obese
premenopausal women and cardiovascular risk markers or
insulin resistance.
2. Patients and Methods
2.1. Patients. Forty eight premenopausal obese patients, aged
35–52 years (32.6 ± 10.3 year), with a BMI of 36.0 ±
6.4 kg/m2, were studied (Table 1). None of the obese patients
had diabetes mellitus or other medical problems nor were
they taking any drugs. All subjects had regular menses.
The subjects had been eating a weight-maintaining diet for
several weeks prior to the study. All the studies have been
conducted in accordance with the declaration of Helsinki. All
subjects provided informed consent and approval for this
study was obtained from the hospital committee.
2.2. Study Procedure. Between 08:30 and 09:00 AM, after an
overnight fast and while seated, a peripheral venous line was
obtained. Fifteen minutes later GHRH (100 micrograms, iv,
0 minutes) was administered. We obtained blood samples
Table 1: Clinical characteristics, cardiovascular risk markers, and
hepatic aminotransferases in obese premenopausal women (n =
48).
Mean ± SEM
Age (year) 32.6 ± 2.6
BMI (kg/m2) 36.0 ± 1.6
Mid-waist circumference (cm) 102.4 ± 3.4
Waist/hip ratio 0.90 ± 0.02
Total body fat (%) 38.7 ± 1.5
Trunk fat (cm2) 141.9 ± 10.2
GH Peak (ng/mL) 10.4 ± 1.8
IGF-I (ng/mL) 147.3 ± 69.0
Total cholesterol (mg/dL) 177.1 ± 11.2
HDL (mg/dL) 52.6 ± 2.0
LDL (mg/dL) 106.3 ± 9.6
Triglyceride (mg/dL) 102.4 ± 18.3
Fasting glucose (mg/dL) 95.7 ± 2.0
Fasting Insulin (μU/mL) 13.0 ± 0.5
HOMA-IR 3.3 ± 0.5
TAS 122.5 ± 3.5
TAD 76.5 ± 3.2
Leptin (ng/mL) 24.3 ± 13.5
GOT (IU/L) 21.4 ± 8.0
GPT (mIU/L) 24.9 ± 12.7
GGT (IU/L) 25.6 ± 27.3
for GH at baseline (0 minutes) and then at times 15, 30,
60, 90, and 120 minutes. Fasting blood was drawn for
IGF-I, serum cardiovascular risk markers, and hormonal
determinations. Mid-waist circumference was measured as
the midpoint between the iliac crest and the lowest rib, with
the patient in the upright position. Measurement of the
hip circumference was performed at the widest point, also
with the subject in an upright position. Total body fat was
calculated through bioelectrical impedance analysis (BIA).
BIA is based on measurement of the transmission speed of
a 1/4 volt electrical pulse between electrodes at the feet and
hands. Because fat-free mass is comprised of water, proteins,
and electrolytes, and conductivity is greater in fat-free mass
than in fat mass [32]. Resistance and reactance are used
to estimate total body water, and by extension, fat mass
and lean mass, with the latter including bone [33]. Truncal
fat was calculated through the Lemieux formula based on
anthropometric parameters [34].
2.3. Assays and Other Methods. Serum samples were col-
lected and stored at −80 C. Serum GH (μg/L) was mea-
sured by a solid-phase, two-site chemiluminescent enzyme
immunometric assay (Immulite, EURO/DPC) with a sensi-
tivity of 0.01 μg/L and with intrassay coeﬃcients of variation
of 5.3%, 6.0%, and 6.5% for low, medium, and high plasma
GH levels, respectively; and with interassay coeﬃcients of
variation of 6.5%, 5.5%, and 6.6% for low, medium, and
high plasma GH levels, respectively. IGF-I (ng/mL) was
determined by a chemiluminescence assay (Nichols Institute,
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San Clemente, CA, USA) and with intrassay coeﬃcients of
variation of 4.8%, 5.2%, and 4.4% for low, medium and high
plasma IGF-I levels, respectively, and with interassay coeﬃ-
cients of variation of 7.7%, 7.4%, and 4.7% for low, medium,
and high plasma IGF-I levels, respectively. Insulin (μU/mL)
was measured with a solid-phase two-site chemilumines-
cent immunometric assay (Immulite 2000 Insulin, DPC,
Los Angeles, CA, USA) and with intrassay coeﬃcients of
variation of 5.5%, 3.3%, and 3.7% for low, medium and high
plasma insulin levels, respectively, and with interassay coeﬃ-
cients of variation of 7.3%, 4.1%, and 5.3% for low, medium,
and high plasma insulin levels, respectively. Leptin (ng/mL)
was measured by radioimmunoassay (Mediagnost, Tubigen,
Germany) and with intrasay and interassay coeﬃcients of
variation of 5.3% and 13.6%, respectively. Glucose, total,
HDL, and LDL cholesterol, triglycerides, glutamic oxalacetic
transferase (GOT), glutamic pyruvic transferase (GPT), and
gamma glutamyl transferase (GGT) were measured using
standard laboratory previously described methods [35].
All samples from a given subject were analysed in the
same assay run. The area under the secretory curve (AUC)
was calculated by a trapezoidal method. Insulin resistance
was calculated on the basis of fasting values of plasma
glucose and insulin, according to the homeostasis model
assessment (HOMA-IR) method [36] as follows: HOMA-IR
= fasting insulin levels × fasting glucose levels/22.5, where
basal insulin levels is in μU/mL, and glucose is in mmol/L.
2.4. Statistical Analysis. The results are presented as mean
values ± SEM. All comparisons were based on univariate,
nonparametric tests. Intragroup comparisons were based on
Mann-Whitney test. Numerical correlations were analyzed
using Spearman’s correlation test. P values ≤ .05 were
considered to be significant. For graphic presentation we use
mean values ± SEM. The SPSS software 12.0 (Chicago, IL,
USA) was used to produce statistical analysis.
3. Results
3.1. Clinical Characteristics and Analytical Data of Study
Subject. Clinical characteristics, cardiovascular risk markers,
and hepatic aminotransferases are shown in Table 1. The age
range of study participants was 32–48 years, and the BMI
ranged from to 30.4 to 52.2 kg/m2. Subjects were arbitrarialy
classified as meeting the criteria for GH deficiency (GHD)
when peak GH after stimulation with GHRH was ≤3 ng/mL;
although GHRH alone is not a well-validated test for the
diagnosis of GH deficiency, this cutoﬀ point is based on stan-
dard criteria used to diagnose adults with hypopituitarism
after various stimuli [37, 38]. GH secretion after stimulation
with GHRH at the diﬀerent time points in the entire group is
shown on Figure 1.
Clinical characteristics, cardiovascular risk markers,
and hepatic aminotransferases in GH-Deficient and GH-
Suﬃcient obese women are presented in Table 2. 23% of
obese women met our stablished criteria for GHD based on
the response to GHRH. The group of the patients classified
as meeting hypopituitary GHD criteria had a mean BMI of
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Figure 1: Mean ± SEM GH secretion in obese premenopausal
women after stimulation with GHRH.
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Figure 2: Mean± SEM peak GH secretion in obese premenopausal
women after stimulation with GHRH, divided in two groups, above
or below BMI median (P = .005).
45.5 ± 6.3 kg/m2, with a midwaist circumference of 117 ±
9.2 cm, significantly higher than in obese patients with GH
suﬃciency (P = .007 for BMI and P = .039 for midwaist
cicumference). The group of patients with peak GH after
stimulation ≤3 μg/L had a tendency to a higher mean age
than the group of patients with peak GH after stimulation
>3 μg/L, 42.3 ± 9.0 versus 30.4 ± 9.4 , respectively, although
the diﬀerence was not significant.
3.2. Relation of Peak-Stimulated GH to Measures of Adiposity.
When the patients were divided in two groups, above or
below BMI median, peak GH secretion was 15.2 ± 2.0 and
5.6 ± 1.8 (μg/L) for patients above or below the median,
respectively (P = .005) (Figure 2). BMI was strongly and
inversely associated with peak GH after stimulation with
GHRH (R = −0.721, P = .022). Peak GH secretion was
strongly and inversely associated with waist circumference
(R = −0.576, P = .020), percentage of total body fat (R =
−0.748, P = .001), and trucal fat (R = −0.595, P = .019).
These associations remained significant after controlling for
age.
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Table 2: Cardiovascular risk markers and hepatic aminotransferases (Mean ± SEM) in GH-Deficient and GH-Suﬃcient Obese
premenopausal women.
GH Peak (≤3 ng/mL) GH Peak (>3 ng/mL) P value
n = 9 N = 39
Age (year) 42.3± 2.3 30.4± 2.4 NS
BMI (kg/m2) 45.5± 1.6 33.8± 1.0 .007
Mid-waist circumference (cm) 117± 2.3 99.0± 3.1 .039
Waist/hip ratio 0.97± 0.04 0.89± 0.02 NS
Total body fat (%) 46.9± 1.0 36.8± 1.2 .004
Trunk fat (cm2) 185.0± 6.7 131.2± 9.2 .048
IGF-I (ng/mL) 103.3± 6.5 158.3± 18.2 NS
IGFBP-3 4.9± 0.2 4.6± 0.3 NS
Total cholesterol (mg/dL) 231± 14.0 165± 8.3 .039
HDL (mg/dL) 43.5± 2.0 54.2± 1.8 NS
LDL (mg/dL) 173± 2.5 95.2± 7 .044
Triglyceride (mg/dL) 172± 29.5 86.4± 13.4 .047
Fasting glucose (mg/dL) 99.7± 2.0 91.7± 2.0 NS
Fasting Insulin (μU/mL) 20.9± 0.3 10.8± 1.3 .005
HOMA-IR 5.3± 0.25 2.6± 1.5 .018
Leptin 20.1± 3.5 24.7± 3.6 NS
GOT (IU/L) 31.3± 2.0 17.6± 1.0 .012
GPT (IU/L) 42.3± 4.4 20.2± 1.5 .022
GGT (IU/L) 65.0± 9.2 13.8± 1.2 .007
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Figure 3: Mean ± SEM total and LDL cholesterol in GH-Deficient
and GH-Suﬃcient Obese patients (P = .044).
3.3. GH Secretion Parameters and Cardiovascular Risk Mark-
ers, Insulin Resistance Indices, andHepatic SerumAminotrans-
ferases. Mean levels of cardiovascular risk markers, hepatic
aminotransferases, and insulin resistance were compared
between in GHD and GH-Suﬃcient obese patients (Table 2).
Mean total and LDL cholesterol were higher, in subjects who
would have been classified as GHD based on hypopitutary
criteria compared with GH-suﬃcient subjects (P = .039
and P = .044, resp.) (Figure 3). Mean serum hepatic
aminotransferases, GOT, GPT, and GGT, were all higher,
in subjects who would have been classified as GHD based
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Figure 4: Mean ± SEM hepatic serum aminotransferases: GOT
(P = .012), GPT (P = .022), and GGT (P = .007) in GH-Deficient
and GH-Suﬃcient Obese patients.
on hypopitutary criteria when compared with GH-suﬃcient
subjects (P = .012, P = .022, and P = .007, resp.) (Figure 4).
Mean fasting insulin and HOMA-IR were higher, in the
group of patients with peak GH after stimulation ≤3 μg/L
when compared with the group of patients with peak GH
after stimulation >3 μg/L (P = .005 and P = .018, resp.)
(Figure 5). These diﬀerences were no longer significant after
controlling for measures of adiposity whether BMI, mid-
waist circumference, or trunk fat.
Correlations between GH secretion or IGF-I and car-
diovascular risk markers or aminotransferases are shown in
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Figure 5: Mean ± SEM fasting insulin (P = .005) and HOMA-IR
(P = .018) in GH-Deficient and GH-Suﬃcient Obese patients.
Table 3: Correlations between GH secretion or IGF-I and cardio-
vascular risk markers or aminotransferases levels.
GH Peak IGF-I
r P r P
Age (year) −0.543 .030 −0.486 .066
BMI (kg/m2) −0.721 .022 −0.577 .024
Mid-waist circumference (cm) −0.576 .020 −0.338 .218
Waist/hip ratio −0.350 .184 −0.229 .411
Total body fat (%) −0.748 .001 −0.728 .002
Trunk fat (cm2) −0.595 .019 −0.338 .218
GH Peak 0.599 .018
IGF-I (ng/mL) 0.599 .018
Total cholesterol (mg/dL) −0.532 .034 −0.513 .051
HDL (mg/dL) 0.561 .037 0.568 .043
LDL (mg/dL) −0.692 .006 −0.725 .005
Triglyceride (mg/dL) −0.456 .076 −0.468 .078
Fasting Insulin (μU/mL) −0.650 .012 −0.506 .078
HOMA-IR −0.846 .001 −0.613 .034
GOT (IU/L) −0.685 .020 −0.049 .894
GPT (IU/L) −0.656 .011 −0.257 .397
GGT (IU/L) −0.642 .018 −0.408 .188
Table 3. Peak GH secretion after stimulation with GHRH was
inversely associated with total (R = −0.532, P = .034) and
LDL cholesterol (R = −0.692, P = .006) and positively
associated with HDL cholesterol (R = 0.561, P = .037). Peak
GH secretion after stimulation with GHRH was inversely
associated with serum hepatic aminotransferase, GOT (R =
−0.685, P = .020), GPT (R = −0.656, P = .011), and GGT
(R = −0.642, P = .018). Peak GH secretion after stimulation
with GHRH was inversely associated with fasting insulin
(R = −0.650, P = .012) and HOMA-IR (R = −0.846, P =
.001). These correlations were no longer significant after
controlling for measures of adiposity whether BMI, mid-
waist circumference, or trunk fat.
IGF-I was strongly and inversely associated with BMI
(R = −0.577, P = .024) and percentage of total body fat
(R = −0.728, P = .002). IGF-I was strongly negatively
associated with LDL cholesterol (R = −0.725, P = .005) and
positively associated with HDL-cholesterol (R = 0.568, P =
.043). IGF-I was strongly negatively associated with HOMA-
IR (R = −0.613, P = .034). These correlations were
no longer significant after controlling for measures of
adiposity whether BMI, mid-waist circumference, or trunk
fat. HOMA-IR was strongly and positively associated with
serum hepatic aminotransferases, GOT (R = 0.821, P =
.023), GPT (R = 0.705, P = .023), and GGT (R =
0.693, P = .026).
4. Discussion
We have found a strong inverse relationship between BMI or
indices of central adiposity and peak-stimulated GH levels.
The presence of decreased GH secretion is associated with
a deleterious cardiovascular marker risk profile, increases
in total and LDL cholesterol. We report strong inverse
associations of GH peak after stimulation by GHRH in a
group of obese otherwise healthy premenopausal women
with traditional lipoprotein cardiovascular risk markers. Our
results are similar to those of Utz et al. [28], although
they found significant diﬀerences with other cardiovascular
risk factors, mainly nontraditional, in that study HDL was
lower, hsCRP (high-sensitivity C-reactive protein), and TNF-
α receptor I higher, in young overweight or obese women
meeting GHD criteria than in women with GH suﬃciency.
In contrast to Utz et al. data, in this study the increase in
total and LDL cholesterol was no longer significant after
controlling for measures of adiposity whether BMI, mid-
waist circumference, or trunk fat. These diﬀerences could
be due in part to the diﬀerent stimulus employed or to
the diﬀerent patient group; we include only obese women
without other disease, or to the use of indirect indices of
visceral fat. We think that all these data raise the question of
whether decreased endogenous GH secretion may contribute
to an elevated risk of future cardiovascular events in young
obese women.
The primary cause of the impaired GH secretion of obe-
sity could be an altered hypothalamus, abnormal pituitary
function, or a perturbation of the peripheral signals acting at
either the pituitary or hypothalamic level. There are diﬀerent
studies that suggest that the pathophysiological mechanism
responsible for the GH hyposecretion of obesity is probably
multifactorial; there is a chronic state of somatostatin
hypersecretion, increased FFA and decreased ghrelin [39–
44]. Quite surprisingly, we found in the present study
that decreased GH secretion was associated with increased
levels of serum hepatic aminotransferases. We report a
strong inverse association of GH peak after stimulation by
GHRH in a group of obese otherwise healthy premenopausal
women with increased hepatic aminotransferases. As far
as we know, there has not been previously published
such a relationship. Although there are some recent data
that suggest that GH deficiency could participate in the
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pathogenesis of nonalcoholic fatty liver disease [45]. We
hypothesize that the mechanism of that correlation is a
manifestation of hepatic insulin resistance. It has been found
that the higher the BMI, the higher the prevalence of elevated
liver enzymes, and the presence of insulin resistance was
highly predictive of elevated hepatic enzymes, suggesting an
important role for insulin resistance in nonalcoholic fatty
liver disease [46]. In our study HOMA-IR was strongly and
positively associated with serum hepatic aminotransferases.
The presence of decreased GH secretion is associated with
increased serum insulin levels and insulin resistance indices.
Moreover, we report a strong inverse association of GH
peak after stimulation with GHRH and the insulin resistance
indices, HOMA-IR. The importance of fasting insulin in GH
secretion has been found in some studies [29, 47]. There is
also clinical [48] and experimental [49] evidence suggesting
an important role for insulin as a direct inhibitor of GH
secretion. All these data suggest that insulin resistance could
be another factor responsible for the altered GH secretion of
obesity.
In accordance with previous studies [50, 51] we have
found that in the presence of decreased GH secretion, IGF-I
levels were normal, although IGF-I was positively associated
with peak GH secretion. But IGF-I was strongly and inversely
associated with BMI and insulin resistance (HOMA-IR).
These data suggest, on one hand, that IGF-I is still GH
dependent in obesity, but that there are other factors such as
insulin or others [51] that regulate IGF-I levels. On the other
hand that the decreased GH secretion of obesity is not due to
increased IGF-I levels as previously suggested [52].
There are many common features between subjects with
GHD due to pituitary disease and subjects with a clustering
of cardiovascular risk factors in the absence of pituitary
disease, but it is not clear whether the low GH associated
with these cardiovascular risk factors is cause or eﬀect.
Low GH in the setting of obesity has been shown to be
reversed with weight reduction, implying that it is obesity
that causes the low GH [19, 30]. By contrast, the observation
that subjects with GHD due to pituitary or hypothalamic
disease develop obesity and its metabolic consequences [1–
3], and that some cardiovascular risk factors are inversely
related to GH independently of obesity indices [28], suggests
that GH plays a physiological role in the development of
obesity and its cardiovascular complications. This distinction
is important in our understanding of the role of GH in the
development and maintenance of cardiovascular risk factors
and may have therapeutic implications.
Although our data do not diﬀerentiate between low
GH being a cause or an eﬀect of these cardiovascular risk
factors, they indicate that the relationship between low GH
and increased cardiovascular risk may be physiologically
important in the absence of pituitary disease. Another
limitation that should be considered in this study is the lack
of a control lean group. These data in a group of obese
young women showing a clear correlation of low GH to
individual cardiovascular risk factors suggest an important
role for GH in the clustering of these risk factors, whether
or not the relationship is a causative one. Analogous to
the gradual acceptance of a wide variety of what are now
considered traditional cardiovascular risk factors, perhaps it
is time to consider low GH as an independent marker for
cardiovascular disease [29].
5. Conclusions
In conclusion, we have found that obese premenopausal
women with decreased GHRH-induced GH secretion when
compared with obese patients with GH suﬃciency, have
increased total cholesterol, LDL cholesterol, liver enzymes,
fasting insulin and HOMA-IR, when compared with obese
patients with GH suﬃciency. There was a significant negative
correlation between peak GH secretion and total cholesterol,
LDL cholesterol, liver enzymes, fasting insulin or HOMA-
IR. There was a significant positive correlation between IGF-
I and peak GH and a negative correlation between IGF
and HOMA-IR, but IGF-I levels were not decreased in the
GHD group. We think that these data strongly suggest a
role for insulin resistance in the decreased GH secretion
of obesity, and the concept that the blunted GH secretion
of central obesity could be the pituitary expression of the
insulin resistance (metabolic) syndrome.
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